Pulse Biosciences Files 8-K: Officer/Director Changes & Financials

TL;DR

Pulse Biosciences 8-K dropped: leadership shakeup, financials out. Watch closely.

AI Summary

Pulse Biosciences, Inc. filed an 8-K on February 4, 2025, reporting on events as of January 31, 2025. The filing includes information regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also covers Regulation FD disclosures and financial statements and exhibits.

Why It Matters

This filing provides crucial updates on the company's leadership and financial reporting, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: medium — Changes in directors or officers, along with financial disclosures, can indicate shifts in company strategy or performance that may carry inherent risks.

Key Players & Entities

• PULSE BIOSCIENCES, INC. (company) — Registrant
• January 31, 2025 (date) — Date of Earliest Event Reported
• February 4, 2025 (date) — Filing Date
• 001-37744 (company) — SEC File Number
• 46-5696597 (company) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — ange on Which Registered Common stock, $0.001 par value per share PLSE The Nasdaq
• $400,000 — ment. His current annual base salary is $400,000 and he is eligible for an annual target
• $56,000 — l also receive a sign-on bonus of up to $56,000. In connection with his appointment, t
• $20.93 — common stock, with an exercise price of $20.93 per share, the closing price of the Com
• $2.0B — alization of not less than two billion ($2.0B) for 270 consecutive calendar days and
• $8 million — the Company has generated not less than $8 million of GAAP product revenue over twelve mon
• $3.0B — ization of not less than three billion ($3.0B) for 270 consecutive calendar days and
• $48 million — the Company has generated not less than $48 million of GAAP product revenue over twelve mon
• $4.0B — lization of not less than four billion ($4.0B) for 270 consecutive calendar days and
• $115 million — the Company has generated not less than $115 million of GAAP product revenue over twelve mon
• $5.0B — lization of not less than five billion ($5.0B) for 270 consecutive calendar days and
• $175 million — the Company has generated not less than $175 million of GAAP product revenue over twelve mon

Filing Documents

• plse20250131_8k.htm (8-K) — 35KB
• ex_773340.htm (EX-10.1) — 74KB
• ex_773341.htm (EX-99.1) — 10KB
• 0001437749-25-002664.txt ( ) — 274KB
• plse-20250131.xsd (EX-101.SCH) — 3KB
• plse-20250131_def.xml (EX-101.DEF) — 11KB
• plse-20250131_lab.xml (EX-101.LAB) — 15KB
• plse-20250131_pre.xml (EX-101.PRE) — 11KB
• plse20250131_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Appointment Pulse Biosciences, Inc. (the "Company") has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025 (the "Start Date"). In connection with his appointment, Mr. Skinner will also serve as the Company's principal financial officer. Mr. Skinner most recently served as Vice President, FP&A and Investor Relations at Copeland, a private equity backed industrial company. Prior to this role, Mr. Skinner was Vice President, Finance and Corporate Development at Imperative Care, a venture backed medical technology company. There, he spearheaded M&A, strategy, partnerships, and sales operations along with providing financial and strategic support for all development stage business units. While at Imperative Care, he also served as the interim CFO of Kandu Health during its spin-out and fundraising process. Prior to his time at Imperative Care, Mr. Skinner served as Vice President, Finance – Interventional Urology at Teleflex (NYSE: TFX), a global medical technology company. There he led accounting, FP&A, customer service, and sales operations for the Interventional Urology Business Unit, following his role as Senior Director, Corporate Development, where he helped close 25 M&A transactions. Prior to Teleflex, Mr. Skinner spent time at Axalta Coating Systems (NYSE: AXTA) working on its carve-out and IPO and at Duff & Phelps (now Kroll) in the Valuation Advisory Group. Mr. Skinner holds a Bachelor of Science and a Master of Business Administration from The Ohio State University. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. Skinner. Mr. Skinner was not selected to serve as the Company's Chief Financial Officer pursuant to any arrangement

01

Item 7.01 Regulation FD Disclosure. On February 4, 2025, the Company issued a press release announcing the appointment of Mr. Skinner as Chief Financial Officer. A copy of the Company's press release is attached as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Employment Agreement 99.1 Press Release of Pulse Biosciences, Inc. dated February 4, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: February 4, 2025 By: /s/ Paul A. LaViolette Paul A. LaViolette Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR